A role for neurotensin in bicalutamide resistant prostate cancer cells
- 16 October 2006
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 67 (2) , 190-202
Abstract
BACKGROUND Anti-androgens are administered as a principal treatment for prostate cancer. Aggressive hormone refractory disease is characterized in some cases by the development of a neuroendocrine phenotype. However little attention has been paid to resistance pathways selected for by long-term treatment with non-steroidal anti-androgens. METHODS Using a resistant sub-line, LNCaP-Bic, we performed a comparative gene expression profiling using cDNA microarrays and target validation by qRT-PCR. Targets were then explored using cell proliferation, cell cycle analysis and in vitro invasion assays using siRNA technology. RESULTS Neurotensin/Neuromedin N (NTS) was upregulated in the LNCaP-Bic line at both the transcript and protein level. The resistant line was found to have an increased proliferation rate, more rapid cell cycle progression and increased invasiveness through Matrigel. Each phenotypic difference could be reduced using siRNA knockdown of NT. CONCLUSION Increased expression of NT in bicalutamide resistant prostate cancer cells induces cell proliferation and invasion suggesting that this peptide may contribute to the development of bicalutamide resistant prostate cancer. ProstateKeywords
This publication has 42 references indexed in Scilit:
- The androgen receptor pathway is by‐passed in prostate cancer cells generated after prolonged treatment with bicalutamideThe Prostate, 2005
- A Human- and Male-Specific Protocadherin that Acts through the Wnt Signaling Pathway to Induce Neuroendocrine Transdifferentiation of Prostate Cancer CellsCancer Research, 2005
- Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment ModalitiesEuropean Urology, 2005
- Influence of Native and Hypochlorite-Modified Low-Density Lipoprotein on Gene Expression in Human Proximal Tubular EpitheliumThe American Journal of Pathology, 2004
- Production of Recombinant Large Proneurotensin/Neuromedin N-Derived Peptides and Characterization of Their Binding and Biological ActivityBiochemical and Biophysical Research Communications, 2002
- Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor CellsMolecular and Cellular Biology, 2001
- EXPRESSION OF MATRIX METALLOPROTEINASE-7 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 IN HUMAN PROSTATEJournal of Urology, 1998
- Matrilysin: An epithelial matrix metalloproteinase with potentially novel functionsThe International Journal of Biochemistry & Cell Biology, 1996
- Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocine phenotypeJournal of Cellular Biochemistry, 1996
- Structure and functional expression of the cloned rat neurotensin receptorNeuron, 1990